Novo Nordisk (NVO) closed at $38.42 in the latest trading session, marking a -1.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.41%. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq added 1.11%. Shares of the drugmaker have depreciated by 10.2% over the course of the past month, underperforming the Medical sector's gain of 1.97%, and the S&P 500's gain of 1.46%. The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. The company's upcoming EPS is projected at $0.81, signifying a 20.59% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $11.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.